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Inhaled formulations are promising for pulmonary and systemic non-pulmonary diseases.
Functional engineered particles including drugs and drug-loaded nanocarriers have been
anticipated because they can improve drug delivery efficacy against target sites in the
lungs or blood. In this review, unique spray nozzles (e.g., four-fluid spray nozzle and two-
solution mixing type nozzle) for the preparation of nanocomposite particles which mean
microparticles containing drug nanoparticles are described. These nozzles can produce
nanocomposite particles in one-step and their spray drying system is suitable for scaling-
up. Nanocomposite particles are useful in improving drug absorption and delivery efficacy
against alveolar macrophages. In addition, recent studies on several pulmonary diseases
(tuberculosis, lung cancer, cystic fibrosis, pneumonia, vaccine and others) and related
inhaled formulations were also reviewed.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Pulmonary drug administration has the potential of a non-
invasive and easy administration method. It has attracted
much attention in the field of pulmonary and non-pulmonary
diseases for decades because of the specific structure and
function of lung tissue; the lungs have large surface area, thin
mucosal cell membrane, and blood vasculature. Alveoli,
which are the site of oxygen and carbon dioxide exchange,fax: þ81 52 836 3464.
(T. Ozeki).
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ns.org/licenses/by-nc-ndcontain blood capillaries at high density. In addition, drugs
can easily penetrate the thin layer of alveolar endothelial cells
and enter the blood. Compared with the oral administration,
pulmonary administration avoids the hepatic metabolism,
which is known as first-pass effect. Moreover, the lungs
contain lymph nodes and present immune competent cells.
Therefore, various drugs and vaccine delivery systems tar-
geting the lungs have been developed.
Currently, both liquid aerosol and dried powder formula-
tions have been used in pulmonary administration and somesity.
d hosting by Elsevier B.V. This is an open access article under the
/3.0/).
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tionally, the recently approved products of inhaled formula-
tion was summarized in Table 1. Although the administration
of aerosol by nebulizer has been established, dried formula-
tion is superior to liquid aerosol from the stability perspective.
However, the diameter of the dried powder should be
controlled. The optimization of aerodynamic diameter is
necessary to achieve delivery into deeper regions such as the
alveoli [2]. In addition, the change in the surface morphology
can affect the aerodynamic diameter, and porous and wrin-
kled particles have been developed [3].
In this review, two special spray nozzles were introduced.
Spray nozzles have been established to prepare drug “nano-
composite particles”, which are microparticles containing
drug nanoparticles. These composites are useful for the
preparation of inhaled formulations against pulmonary and
systemic non-pulmonary diseases. Moreover, recent studies
focusing on inhaled drug formulations with or without drug
carriers were reviewed.2. One-step preparation of nanocomposite
particles by spray dryer equipped with special
spray nozzles
The pulmonary administration has recently been anticipated
to improve the absorption of poor water-soluble drugs.
Approximately 40% of potential therapeutic compounds are
water-insoluble compounds that are classified as bio-
pharmaceutics classification system (BCS) class 2 or 4. A
common method for improving drug absorption is the size
reduction of bulk drugs (e.g., nanoparticles drugs), which
could enhance their solubility because of the increase in their
surface area. Furthermore, nanoparticle drugs could be more
easily absorbed into the blood.
However, the beneficial properties of nanoparticles are
often easily lost by self-agglutination and their redispersion is
very difficult. The prevention of self-agglutination is an
important issue and some solutions have been developed,
such as reducing their dimensions to the order of microns,
which means the preparation of nanocomposite particles. In
our group, nanocomposite particles have been prepared using
a spray dryer equipped with a unique spray nozzle.Table 1 e Recent product of inhaled formulations in the
market.
Name Drug Category Device
Alvesco® Ciclesonide Steroid pMDI
Asmanex® Mometasone Steroid DPI
Adoair® Fluticasone and Salmeterol Combination pMDI
Symbicort® Budesonide and Formoterol Combination DPI
Oxis® Formoterol LABA DPI
Onbrez® Indacaterol LABA DPI
Spiriva® Tiotropium LAMA SMI
Seebri® Glycopyrronium LAMA DPI
Afrezza® Insulin Diabetes DPI
Abbreviation: pMDI: pressurized metered-dose inhaler, DPI: dry
powder inhaler, SMI: soft mist inhaler, LABA: long-acting beta
agonist, LAMA: long-acting muscarinic antagonists.Four-fluid spray nozzle is a unique spray nozzle containing
two liquid passages and two air passages (Fig. 1) (Fujisaki
Electric Co.; http://www.fujisaki-hest.com). Compressed air is
flown from the air passages to transform solutions into mist.
The solution flown in the passages is mixed with compressed
air and the solution is accelerated. The collision of the com-
pressed air at the end of the nozzle generates a shockwave
that transforms the solution into single micron mist. The
single micron mist is quickly and efficiently dried because of
its reduced size and increased surface area. For example, poor
water-soluble drugs are dissolved in an organic solvent and
the solution is flown in one passage. Then, mannitol (MAN)
aqueous solution is flown into the other passage. The drug-
organic mist and MAN-aqueous mist are mixed at the end of
the nozzle, where the drug starts crystallizing by anti-solvent
effect, which is the phenomenon in which solubility change
induces the precipitation of the drug. The drug/MAN mist is
immediately spray-dried until the drug crystallization has
been completely progressed. Thus, relatively small drug
nanoparticles are produced in MAN microparticles. Because
one-step preparation and large amount of nanocomposite
particles can be obtained by spray drying, the method is
suitable for scaling-up. In previous studies, composites of
flurbiprofen/salicylate [4], polymer/MAN [5], rifampicin/MAN
[6], and rifampicin/polymer/MAN [7] were developed using the
spray dryer equipped with a four-fluid spray nozzle.
Although the four-fluid spray nozzle is useful in the one-
step preparation of nanocomposite particles, optimization
of spray drying conditions has been sometimes necessary,
and it has been unclear if the anti-solvent effect occurred
efficiently. Therefore, a two-solution mixing type nozzle has
been developed to prepare nanocomposite particles (Fig. 2)
(Ohkawara Kakohki Co.; http://www.oc-sd.co.jp/english/
index.html). In this device, similar to the four-fluid spray
nozzle, the two solutions are separately flown in different
passages and are mixed in the mixing chamber in the nozzle.
The drug solution dissolved in organic solvent is added into
the MAN-aqueous solution in the mixing parts and the
mixture is immediately spray-dried. Anti-solvent effect
properly occurs in the mixing parts of the nozzle, and we
speculate that the preparation of the nanocomposite parti-
cles is achieved in suitable conditions. The spray nozzle is
customizable and some parts of it can adjust the mixing
condition. Ethylcellulose (EC) is a poor water-soluble poly-
mer, which was used as the model compound; EC/MAN
composite was prepared using a spray dryer equipped with
the two-solution mixing type spray nozzle [8]. The composite
particles prepared with this method exhibited relatively
small diameter compared with those prepared using the
four-fluid spray nozzle. To extend our study, microparticles
containing solid dispersion drug nanoparticles were prepared
[9]. Solid dispersion is a technique used to increase drug
dissolution and absorption. Solid dispersion of nanoscale
drugs showed enhanced intestinal absorption compared with
composites containing drug nanoparticles and original drug
powders. Although a detailed investigation about on the
inner structure, crystallinity, and physical stability of mi-
croparticles is required in the study, these unique nano-
composite particles are promising formulations to enhance
the absorption of poor water-soluble drugs.
Fig. 1 e A four-fluid spray nozzle (simplified image) and preparation of nanocomposite particles.
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and non-pulmonary diseases
Various types of inhaled formulation have been recently
developed. These formulations target various pulmonary
diseases such as asthma, chronic obstructive pulmonary dis-
ease (COPD), cystic fibrosis, lung cancer, pneumonia derived
from bacterial infection, and tuberculosis. In this review,
recent studies about inhaled formulations specific for several
pulmonary diseases were reviewed. The summary of articles
in this review was shown in Table 2.3.1. Tuberculosis
Tuberculosis is an infectious disease spread worldwide and
primarily occurs in south Saharan regions. Patients with HIV
are easily infected with TB and the co-infection yields com-
plications [10]. The infection mechanism has been well
investigated [11e13]. After the invasion in the lungs by the
airway, the bacterium is digested by alveolar macrophages.
Although several parts of the bacterium are sterilized by
macrophages, other components escape from digestion,
thereby residing for a long term in macrophages and allowingFig. 2 e A two-solution mixing type spray nozzle (simplifiethe bacteria to grow after host immunity decreases. Inhaled
drug formulations have been adopted for tuberculosis and
formulations targeting the alveolar macrophages have been
successfully tested.
The dry powder formulation of nitroimidazopyran, which
is a promising drug against TB, was prepared using spray
drying [14]. The prepared particles were porous with modified
aerodynamic diameters and contained 5% dipalmitoylphos-
phatidylcholine (DPPC), 20% L-leucine, and 75% drug. The
blood concentration profile showed that the concentration of
the drug through pulmonary route was significantly higher
than that of the drug through oral route, which implies that its
pulmonary bioavailability is higher than its oral bioavail-
ability. The same research group evaluated the therapeutic
effect and tissue damage in infected guinea pigs by compari-
sonwith a positive control (i.e., drug/cyclodextrin suspension)
[15].
Poly-(DL-lactide-co-glycolide) (PLGA) microspheres have
been well studied because of their biodegradative properties
and suitable particle size for pulmonary delivery. PLGA has
the advantage of having a long half-life, which can vary from
one week to one year. The Trojan approach (as shown in
Fig. 3), which targets alveolar macrophages containing bac-
teria, has been proposed because PLGA particles, which ared image) and preparation of nanocomposite particles.
Table 2 e Inhaled formulation for various types of pulmonary diseases in recent articles.
Diseases Drug Formulation (Carrier) References
Tuberculosis Nitroimidazopyran DPPC/leucine porous microparticle, Aerosol [14,15]
Rifampicin PLA microparticles [17]
Lung cancer Cisplatin EGF-modified gelatin nanoparticles [19]
GEM Drug alone [20]
GEM Drug alone [21]
GEM Drug alone [22]
Paclitaxel DPPC/DPPE-PEG microparticles [23,24]
DOX Effervescent powder [25,26]
DOX Drug alone [27,28]
DOX, Oligonucleotide Liposomes [29]
Celecoxib PLGA microparticles [31]
Cystic fibrosis Corticosteroids Drug alone [32]
Tobramycin, Clarithromycin Drug nanoparticles [33]
Ketoprofen Drug/leucine powder [34]
Meloxicam Drug/MAN microparticles [35]
Naringin, Gentamicin Drug/leucine powder microparticles [36,37]
Infection disease Tobramycin PVA or chitosan-coated PLGA nanoparticles [38]
Acyl-homoserine lactone acylase Drug/sugar powder [39]
ITZ Drug/TPGS/MAN composite [40]
Vancomycin Liposomes [43]
Vaccine ESAT-6 antigen Virus-like particles [47]
Bacteriophage Drug/sugar powder [48]
Bacteria Bacteria-leucine nano-and micro- structure [49]
85-B antigen PLGA microparticles [50]
DNA encoding Rv1733c antigen PLGA-PEI [51]
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macrophages [16]. Various methods to prepare homogenous
PLGA particles have been investigated. In a recent study,
rifampicin-loaded PLGA microspheres were prepared by
exploiting the supercritical anti-solvent process [17]. The
average particle size was less than 5 mm (>60%) and this
formulation was inhalable.
3.2. Lung cancer
Lung cancer is one of the major types of cancers whose onset
is related to various factors, including tobacco and asbestos.
These continuous stimulations against the squamous
epithelium, alveolar epithelium, and other types of cells in the
lungs can damage genes and induce malignant alterations.
Various anti-cancer drugs alone or in combination are
currently used for the treatment of lung cancer. However,Fig. 3 e Trojan approach: the smart drug delivery fodrug resistance is a challenging issue. Transporters such as
those of the ATP-binding cassette transporter family,
including multidrug resistance proteins, are expressed in the
endothelial cells and other types of cells in the lung tissues
and most types of lung cancer cells overexpress P-glycopro-
teins [18]. One of the strategies to overcome the drug resis-
tance is the use of drug carriers and lipid-based drug carriers
such as liposomes. These drug-loaded carriers are endocy-
tosed by cancer cells and the drugs are then released into the
cytoplasm, thereby escaping from the pumping of P-glyco-
proteins at the cell membrane.
In a recent study, Tseng et al. prepared cisplatin-loaded
EGF-modified gelatin nanoparticles for targeting cancerous
cells in the lung [19]. This formulation showed higher Pt
concentration on the highly EGFR-expressing A549 cells and
showed lower Pt concentration on the low EGFR-expressing
HFL1 cells, resulting in significant cytotoxicity for A549 cells.r persistent bacterium in alveolar macrophage.
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overexpressing cells in murine lung tissue after the adminis-
tration of the aerosol formulation, indicating that this
formulation is useful for EGFR-expressing cancer cells.
Gemcitabine (GEM), which is a nucleoside analog, is
frequently used for the treatment of lung cancer by intrave-
nous infusion. Studies investigating the side effects of pul-
monary administration of GEM have been recently reported.
In a recent report, GEM was administered by aerosol [20] to
four patients and no changes in hematologic toxicity were
observed after the treatment with aerosolized GEM (4 mg/kg);
however, one patient showed pulmonary toxicity. Plasma
concentration of GEM was very low after pulmonary admin-
istration and the side effects were expected to be decreased.
Animal studies on GEM administration by different pulmo-
nary routeswere also conducted [21]. Intratracheal instillation
by tracheotomy (i.t.t.) or orotracheal route (i.t.o.) was per-
formed in rats. Then, pulmonary toxicity was investigated by
checking lung morphology, histopathology, coefficient, wet/
dry weight ratio, cells related with inflammation, and in-
flammatory cytokines. Both i.t.t. and i.t.o. administrations
showed good absolute bioavailability and similar acute lung
injury compared with intravenous route. Preclinical studies
on the use of GEM aerosol in osteosarcoma-bearing dogs were
conducted by translational research [22]. GEM aerosol
formulation induced increased apoptotic effect with
enhanced Fas expression against lung metastatic foci. These
studies indicated that GEM aerosol is an effective treatment
for lung cancer.
Lung surfactant-mimetic microparticles composed of
DPPC and PEG-lipid conjugate of different lengths were also
prepared using spray dryer [23]. Phospholipid microparticles,
which are the major component of lung surfactants, can have
a fate similar to native lipids. Conjugation of PEG on the sur-
face of these particles helps to prevent the recognition of
immune competent cells, including alveolar macrophages,
and enhance the mucus penetration of these particles. The
same research group prepared similar lung surfactant-mimic
particles containing paclitaxel [24].
Doxorubicin (DOX) is used as an anti-cancer drug against
lung cancer. DOX-loaded nanoparticles were incorporated
into inhalable effervescent powder [25]. Lung cancer mouse
model treated with this formulation had its survival signifi-
cantly prolonged compared with mice treated with intrave-
nous injection of DOX. Inhalable nanoparticles remained for
longer duration in the lung tissue, and the radioactivity of the
labeled drug-loaded nanoparticles was not found in the heart
[26]. These results indicated that the side effects of DOX
released from those nanoparticles was minimal. A clinical
trial employing inhaled DOX was also commenced for non-
small cell lung cancer patients [27]. A novel type of inhala-
tion device (OncoMyst Model CDD-2a) was introduced in a
previous study [28] and the combined effect of inhaled DOX
with cisplatin was investigated. The authors concluded that
the combinationwas safe, even though small side effectswere
observed in several patients. As a rational approach, it is
important to overcome drug resistance. Liposomal formula-
tion containing DOX and designed antisense oligonucleotide
(ASO) was used for inhalation [29]. ASO can inhibit the target
mRNA level by designing complementary sequences, and inthat study, ASO against multidrug resistance-associated pro-
tein and Bcl-2, which plays the key role in apoptosis, were
used. This formulation showed high antitumor activity with
fewer side effects than the combination of DOXwith cisplatin.
In the context of administration of inhaled anti-cancer
drug formulations, the safety and protection of researchers
and medical staff is important. Zarogoulidis et al. reviewed
the protection methods used [30] and observed that several
strategies including the use of HEPA filters, protected rooms
(negative-pressure room), hoods and cages were mentioned,
but uniform and global rules are required. In another report,
large porous celecoxib-PLGA microparticles that were pre-
pared using the supercritical fluidmethodwere assessed from
the safety aspect [31]. The microparticles prepared did not
alter the lactate dehydrogenase (LDH), total protein, cell
number in the bronchoalveolar lavage fluid (BAL), collagen
level, and histological analysis.
3.3. Cystic fibrosis
Cystic fibrosis is a disease caused by a mutation in the cystic
fibrosis transmembrane conductance regulator gene and the
immune response to airway infection is the most common
cause of death. The viscosity of mucus derived from the
dysfunction of mucus clearance enhances because of the
infection. Various antibiotics and anti-inflammatory agents
are used for the treatment. Corticosteroids have been used to
reduce lung damages from inflammation. Inhaled corticoste-
roids have been used in children and adults to investigate the
adverse effects [32]. Tobramycin nanoparticles containing
amorphous clarithromycin were prepared using spray drying
[33]. These nanoparticles were classified as dispersible and
porous agglomerates by evaluating the fine particle fraction of
the drug deposition profiles in the lungs. The anti-
inflammatory drug was spray-dried in combination with
leucine, a dispersibility enhancer [34] and showed good in vitro
aerosol performance. A study to understand the drug dissolu-
tionproperties in the lungsusingartificial cysticfibrosismucus
was investigated and the cytotoxicity was evaluated. Melox-
icam/MAN composites were prepared using spray drying [35].
The microparticles contained polymers (PVP and PVA) that
could prevent aggregation. The particles were spherical and
the size was 3e5 mm, which was appropriate for pulmonary
delivery. Prota et al. prepared leucine-based naringin particles
as dispersibility enhancer,whichexhibitedbetter fineparticles
fraction thannaringin-aloneparticles [36]. Gentamicin/leucine
powder was spray-dried to conduct an anti-microbial test [37]
on artificial mucus model. Franz-type vertical diffusion cells
were used and the formulation was loaded on the synthetic
membrane covered by the artificial mucus layer. The mucus
showed delayed permeation from the formulation.
3.4. Infectious diseases (pneumonia)
Pneumonia infection occurs in people whose immunity is
weak. In particular, pneumonia is one of the major causes of
death for elderly persons; thus, a fast therapy to treat it is
important. Antibiotics-loaded PLGA nanospheres embedded
in lactose powder have been prepared [38]. Several hydro-
philic polymers such as PVP and chitosan were used to
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was used to entrap the drug. PVA-modified PLGA nano-
particles reached deep regions of the lungs compared with
chitosan-modified PLGA nanoparticles. The drug formulation
of PvdQ, which is an acyl-homoserine lactone acylase effec-
tive against Pseudomonas aeruginosa, was prepared using
spray freeze-drying [39]. Several types of sugar such as MAN,
trehalose, and inulin were tested. Only trehalose and inulin
stabilized PvdG for 4 weeks at 55 C because of their amor-
phous properties, whereas MAN did not stabilize PvdG
because of its crystalline properties.
Duret et al. prepared itraconazole (ITZ) nanoparticles by
using tocopherol polyethylene 1000 succinate (TPGS) as a
stabilizer for the treatment of invasive pulmonary aspergil-
losis [40]. After optimization, spray-dried ITZ/MAN micro-
particles exhibited good fine particles fraction. This group
prepared ITZ/TPGS/MAN solid dispersion microparticles [41].
The formulation showed improved drug dissolution rate and
saturation solubility. In a recent study, liposomal formulation
was used. Liposomal formulations have been developed
because of their biocompatibility and good drug half-life [42].
Liposomal carriers can add functions on their surface modi-
fications. For example, PEGylation of liposomes could be used
to prolong themucosal clearance. In a recent study, liposomal
vancomycin was nebulized in rats for the treatment of MRSA
pneumonia [43]. Liposomal vancomycin remained in the lung
tissues compared with free vancomycin formulation.3.5. Vaccines
Remarkably, inhaled vaccine also has been developing. The
advantage of pulmonary formulation of vaccines is that the
administration route is the same as that of the infection of
MTB and potent immunity can be supplied [44e46] In addition,
the presence of both bronchoalveolar lymphoid tissue (as
lymph system) and antigen-presenting cells (as immuno-
competent cells) in the lungs, enables the induction of the
immune response. Hundreds of vaccines have been devel-
oped, such as recombinant BCG, BCG overexpressing native
proteins, attenuated MTB, and DNA vaccines. However, inFig. 4 e A scheme of siRNA deliverymany studies, liquid formulations administered by nebulizer
proved to be unstable from the standpoint of preservation.
To induce potent immune response, unique particles were
prepared [47]. Influenza-like nanoparticles containing a pep-
tide having the same sequence of the TB early secretary
antigenic target 6 protein (ESAT-6) was developed. ESAT is a
foreign epitope that has potent T-cell immune response.
These particles exhibited high titers in serum. Spray-dried
preparations of bacteriophages were also used against infec-
tious diseases [48]. One of the main issues of that study
regarded the phage titer after spray drying. In fact, phages are
delicate and suffer temperature increase and shear stress
during the process of spray drying. The phage titer was
different among phages, indicating that the optimization of
the formulation was necessary. Another group prepared a
unique inhaled formulation for tuberculosis [49] consisting of
dried bacterial rod-like structures (1e4 mm in length and
200e400 nm in diameter) coupled with small particles of
leucine (1 mm) The unique nano-microstructure showed drug
efficacy and considerably reduced the bacterial burden in
guinea pigs. A carrier-based inhaled formulation was also
developed and PLGA microparticles containing recombinant
antigen 85-B for TB were inhaled into guinea pigs [50]. The
antigen showed potent immunity and the bacterial burden in
the lung and spleen was reduced. Moreover, a DNA vaccine
encoding the bacterial latency antigen Rv1733c in which the
DNA could bind with the PLGA-polyethyleneimine (PEI) chain
by electric interaction showed enhanced T-cell immune
response [51].
3.6. siRNA delivery for pulmonary diseases
Many pulmonary diseases including lung cancer are malig-
nant, and therefore, gene therapy has been studied from new
approaches. Functional nucleic acids such as small interfering
RNA (siRNA) and plasmid DNA coding therapeutic genes
received much attention in the field of pulmonary delivery
[52]. In particular, the post-transcriptional gene silencing of a
target gene by siRNA is potent compared with the effect
induced by conventional antisense oligonucleotides. In addi-
tion, siRNA is safer than viral vectors. Therefore, siRNA is asystem via pulmonary route.
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molecules (approximately 13 kDa) compared with conven-
tional drugs and are water-soluble. However, although the
penetration of siRNA into the cytoplasm of the target cells
where siRNA can induce RNA interference is an important
step to achieve therapeutic effects, it is difficult for siRNA to
enter the cytoplasm by itself. Some reports indicate that
inhaled siRNA alone can reach the targeted site, but its de-
livery into the cytoplasm is important for the treatment of the
cells of lung tissues.
Cationic lipid-based and polymer-based carriers have been
extensively used for the delivery of siRNA because these car-
riers can deliver the siRNA into the cytoplasm by the inter-
action with the negatively charged cell surfaces and by
endocytosis (Fig. 4). After endocytosis, the siRNA has to avoid
the endosomes before it is degraded by lysosomes. In addition,
cationic carriers can entrap large amount of siRNA by elec-
trostatic interaction, and the entrapped siRNA is protected by
degradation from nucleases. On the other hand, cationic car-
riers influence the gene expression related with apoptosis,
resulting in cytotoxicity. Additionally, it is sometimes difficult
for cationic carrier-based inhaled formulations to reach the
deepest regions of the lungs and the optimization of the
conditions to avoid cytotoxicity and improve delivery effi-
ciency is required.4. Conclusion
Drug delivery technology by inhalation has been progressing
and novel techniques to prepare drug formulations with ease
and cost effectiveness have been developed. The use of two
unique spray nozzles to prepare nanocomposite particles is a
beneficial method for the preparation of water-insoluble drug
nanoparticles and to enhance their preservation. Further-
more, the understanding of details of the target diseases is
important to develop effective drug carriers. The recent
studies reviewed here will be useful for the development of
novel drug formulations.r e f e r e n c e s
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